IGFBP5 antibody (AA 60-272)

Catalog No. ABIN5518921

The Rabbit Polyclonal anti-IGFBP5 antibody has been validated for WB and ELISA. It is suitable to detect IGFBP5 in samples from Human. There are 4+ publications available.

Quick Overview for IGFBP5 antibody (AA 60-272) (ABIN5518921)

Target: IGFBP5 (Insulin-Like Growth Factor Binding Protein 5 (IGFBP5))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This IGFBP5 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Product Details anti-IGFBP5 Antibody

Binding Specificity: AA 60-272

Purpose: Anti-IGFBP5 Antibody Picoband®

Cross-Reactivity (Details): No cross-reactivity with other proteins.

Characteristics: Anti-IGFBP5 Antibody Picoband® (ABIN5518921). Tested in ELISA, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Purification: Immunogen affinity purified.

Immunogen: E. coli-derived human IGFBP5 recombinant protein (Position: A60-E272). Human IGFBP5 shares 96.7% and 96.2% amino acid (aa) sequence identity with mouse and rat IGFBP5, respectively.

Isotype: IgG

Application Details

Application Notes: Western blot, 0.1-0.5 μg/mL, Human
ELISA, 0.1-0.5 μg/mL, -
1. Allander SV, Larsson C, Ehrenborg E, Suwanichkul A, Weber G, Morris SL, Bajalica S, Kiefer MC, Luthman H, Powell DR (May 1994). "Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5". J Biol Chem 269 (14): 10891-8. 2. Butt, A. J., Dickson, K. A., McDougall, F., Baxter, R. C. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J. Biol. Chem. 278: 29676-29685, 2003.

Comment:

We recommend Enhanced Chemiluminescent Kit with anti-Rabbit IgG (ABIN921124) for Western blot.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Concentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

References for anti-IGFBP5 antibody (ABIN5518921)

Wan, Ma, Mei, Shan: "The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells." in: Journal of experimental & clinical cancer research : CR, Vol. 28, pp. 150, (2010) (PubMed).

Hou, Zhang, Liu, Meng, Qiao: "Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology." in: Journal of experimental & clinical cancer research : CR, Vol. 28, pp. 70, (2009) (PubMed).

Khullar, Sehgal: "Evaluation of CIEP and ELISA in a rodent malaria model." in: Indian journal of pathology & microbiology, Vol. 32, Issue 4, pp. 252-5, (1990) (PubMed).

Fruscella: "[Liposuction in plastic surgery]." in: Minerva ginecologica, Vol. 41, Issue 4, pp. 195-7, (1989) (PubMed).

Target Details for IGFBP5

Target: IGFBP5 (Insulin-Like Growth Factor Binding Protein 5 (IGFBP5))

Alternative Name: IGFBP5

Background:

Synonyms: Insulin-like growth factor-binding protein 5,IBP-5,IGF-binding protein 5,IGFBP-5,IGFBP5,IBP5,

Tissue Specificity: Osteosarcoma, and at lower levels in liver, kidney and brain.

Background: Insulin-like growth factor-binding protein 5 is a protein that in humans is encoded by the IGFBP5 gene. The expression of IGFBP5 by stable transfection and adenovirus-mediated infection is inhibitory to growth in 2 human breast cancer cell lines. IGFBP5 expression leads to G2/M cell cycle arrest and apoptosis. Stable expression of IGFBP5 in the breast cancer cell lines also inhibits the formation and growth of tumors following injection in athymic mice. It is concluded that IGFBP5 is a growth inhibitor and proapoptotic agent in breast cancer cells. Additionally, IGFBP-5 is expressed by fibroblasts, myoblasts and osteoblasts, making it the predominant IGFBP found in bone extracts. It has a strong affinity for hydroxyapatite, allowing it to bind to bone cells. When bound to extracellular matrix, IGFBP-5 is protected from proteolysis and potentiates IGF activity, but when it is soluble, IGFBP-5 is cleaved to a biologically inactive 21 kDa fragment (1, 2).

Molecular Weight: 31 kDa

Gene ID: 3488

UniProt: P24593

Pathways: WNT Signaling, Carbohydrate Homeostasis, Myometrial Relaxation and Contraction, Regulation of Carbohydrate Metabolic Process, Autophagy, Smooth Muscle Cell Migration, Growth Factor Binding